Ketofol Versus Dexmedetomidine for Prevention of Emergence Delirium in Pediatric Patients Undergoing Squint Surgeries
Launched by CAIRO UNIVERSITY · Aug 7, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different medications, ketofol and dexmedetomidine, to see which is better at preventing emergence delirium in young children who are having squint surgery. Emergence delirium is a temporary condition where patients might become confused or agitated as they wake up from anesthesia. The study is focused on children aged 2 to 6 years who are generally healthy and scheduled for this type of surgery.
If your child qualifies for this trial, they will receive one of the two medications during their surgery. The study is currently recruiting participants, and it's important to note that parents can choose not to participate if they wish. Additionally, if your child has any known sensitivities to the medications or certain neurological conditions, they may not be eligible for the trial. Overall, this study aims to help improve the recovery experience for children undergoing squint surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • All pediatric patients aged 2 to 6 years.
- • Both sexes.
- • ASA physical status I and II.
- • Patients undergoing squint surgery.
- Exclusion Criteria:
- • • Refusal of parents.
- • Patient sensitivity to any of the study medications.
- • Known neurological disease that can affect the assessment of ED postoperatively.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Cairo, , Egypt
Patients applied
Trial Officials
Karim K Fahim
Study Director
Professor of Anesthesia, Pain management and Surgical ICU Faculty of Medicine, Cairo University.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported